Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The terminal complement complex in sera deficient in the eighth component of complement (C8).

T E Mollnes, T Lea, S Rogde

    Scandinavian Journal of Immunology
    |September 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

    Scientific reports·2024
    Same author

    Robot-assisted partial nephrectomy using the novel Hugo™ RAS system: Feasibility, setting and perioperative outcomes of the first off-clamp series.

    Urologia·2024
    Same author

    Intracellular Complement Component 3 Attenuated Ischemia-Reperfusion Injury in the Isolated Buffer-Perfused Mouse Heart and Is Associated With Improved Metabolic Homeostasis.

    Frontiers in immunology·2022
    Same author

    Acute kidney injury following endovascular intervention for peripheral artery disease.

    The British journal of surgery·2021
    Same author

    Phagocytosis of live and dead Escherichia coli and Staphylococcus aureus in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14.

    Molecular immunology·2019
    Same author

    Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

    Scientific reports·2019
    Same journal

    Recent Thymic Emigrant Levels in Inborn Errors of Immunity: Is Their Diagnostic Value Greater Than We Think?

    Scandinavian journal of immunology·2026
    Same journal

    The EBNA-1 Conundrum: Does Epstein-Barr Virus Invoke Autoimmune Pathology in a Population Subset by Poorly Purine-Loading Its Major Latency-Maintaining Transcript?

    Scandinavian journal of immunology·2026
    Same journal

    Unsupervised Flow Cytometry Reveals a Constant Shift Towards Activated CD4<sup>+</sup> T Cell Subsets in APECED.

    Scandinavian journal of immunology·2026
    Same journal

    RETRACTION: Interleukin-13 Induces T Helper Type 2 Immune Responses in OVA-Immunized BALB/c Mice Bearing a T Cell Lymphoma.

    Scandinavian journal of immunology·2026
    Same journal

    Development of a Detection Method for Soluble Urokinase-Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID-19.

    Scandinavian journal of immunology·2026
    Same journal

    Crohn's Disease Enteritis: Pathophysiological Mechanisms and Therapeutic Approaches.

    Scandinavian journal of immunology·2026
    See all related articles

    Patients with genetic deficiencies in C8 protein showed trace amounts of the terminal complement complex (TCC). Mixing these sera reconstituted C8 activity, significantly increasing TCC levels and indicating partial complement pathway function.

    Area of Science:

    • Immunology
    • Complement System Biology

    Background:

    • The terminal complement complex (TCC) is crucial for the complement system's effector functions.
    • Genetic deficiencies in complement proteins, such as C8, can impair immune responses.

    Purpose of the Study:

    • To investigate the levels and function of the terminal complement complex (TCC) in individuals with genetic deficiencies in C8 alpha-gamma or C8 beta.
    • To assess the impact of C8 reconstitution on TCC formation and terminal complement pathway activity.

    Main Methods:

    • Quantification of TCC in patient sera using immunoassays.
    • Assessment of TCC levels before and after mixing sera from C8-deficient individuals.
    • Zymosan activation assays to stimulate the terminal complement pathway.

    Related Experiment Videos

    Main Results:

    • Sera from C8-deficient patients contained only trace amounts of TCC compared to normal serum.
    • Mixing sera from C8 alpha-gamma and C8 beta deficient individuals reconstituted C8 activity and significantly increased TCC levels.
    • Zymosan activation of individual sera yielded moderate TCC increases, while activation of the reconstituted mixture produced high TCC amounts.
    • C8 protein was detected within the TCC of both deficient sera.

    Conclusions:

    • Functional C8 activity, though present in trace amounts, may exist in individuals with genetic C8 deficiencies.
    • The terminal complement pathway can exhibit partial function even with significant C8 deficiency, potentially explaining its detectability in sensitive assays.